Nancy Wysenski
CIK 1294596 · EVP, Chief Commercial Officer · last filed 2026-07-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$20.22M
Companies
9
Total Filings
85
Lifetime Open-Market Net
-$34.94M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CYTK | Director | 33,992 | $76.76 | $2.61M | $0 | 30 | 2026-07-16 |
| ALKS | Director | 33,028 | $49.17 | $1.62M | -$1.01M | 19 | 2023-07-10 |
| Provention Bio, Inc. (PRVB) Delisted | Director | — | $24.98 | — | $0 | 5 | 2023-04-27 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Director | 0 | — | — | $0 | 4 | 2019-11-12 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Director | — | — | — | $0 | 6 | 2019-06-11 |
| INO | Director | 417 | $0.67 | $279 | $0 | 4 | 2016-05-16 |
| VRTX | EVP, Chief Commercial Officer | 32,232 | $496.07 | $15.99M | -$33.93M | 11 | 2012-06-01 |
| ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted | Chief Operating Officer | 13,054 | $0.29 | $3.8K | $0 | 3 | 2009-03-02 |
| NORTH AMERICAN SCIENTIFIC INC (NASI) Delisted | Director | — | — | — | $0 | 2 | 2008-05-01 |
Recent Filings · Page 2 of 9
85 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-03 | CYTK | Grant (A) | +114 | $0 | EDGAR |
| 2024-05-16 | CYTK | Grant (A) | +5,600 | $0 | EDGAR |
| 2024-01-03 | CYTK | Grant (A) | +74 | $6.2K | EDGAR |
| 2023-10-03 | CYTK | Grant (A) | +224 | $6.2K | EDGAR |
| 2023-07-10 | ALKS | Mixed | +4,527 | -$42.7K | EDGAR |
| 2023-07-05 | CYTK | Grant (A) | +187 | $6.2K | EDGAR |
| 2023-06-30 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2023-05-18 | CYTK | Grant (A) | +5,000 | $0 | EDGAR |
| 2023-05-10 | ALKS | Mixed | — | -$4.7K | EDGAR |
| 2023-05-09 | ALKS | Notice (144) | −41,250 | -$1.29M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.